Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced or returning endometrioid endometrial cancer (a specific type of uterine cancer) that has been confirmed by a doctor.
• People who have at least one measurable area of cancer that can be seen on a CT scan or MRI scan.
• People whose cancer has spread or cannot be removed by surgery without causing serious harm.
• People who have received either no chemotherapy, or no more than one course of chemotherapy for advanced or returning cancer, with the most recent chemotherapy completed at least 3 months before joining (previous chemotherapy given after initial surgery is also counted, with certain limits).
• People who have received non-chemotherapy treatments (such as immunotherapy or hormone therapy) at any point, as long as those treatments ended at least 4 weeks before joining.
• People whose cancer previously responded (shrank or disappeared) to at least one prior treatment, if any prior treatment was received for advanced or returning disease.
• People aged 18 or older.
• People who are generally well enough to carry out light activity and care for themselves (confirm with trial site for the specific fitness level required).
• People whose liver, kidney, and blood cell levels meet certain minimum thresholds on testing (the trial site will check these).
• People whose fasting blood fat levels (triglycerides and cholesterol) are within acceptable ranges on testing.
• People who have recovered from previous treatments or surgeries, with at least 4 weeks having passed since major surgery, radiation, or most prior cancer treatments.
• People who are not pregnant and not breastfeeding, and who agree to use effective contraception from 28 days before starting treatment until 3 months after the last dose, and who agree to regular pregnancy testing throughout the study.
• People who are willing and able to attend scheduled visits and follow study procedures.
• People with a known history of HIV may be eligible if they have had no AIDS-related infections in the past 12 months, have been on a stable HIV treatment regimen for at least 4 weeks with a very low viral count, and whose HIV medications do not interact strongly with the study drug.

Who may not be able to join:

• People who have previously been treated with an mTOR inhibitor, including the study drug nab-sirolimus.
• People with certain specific genetic changes (TSC1 or TSC2 mutations) found in tumour or blood testing, unless a related study has closed to new participants (confirm with trial site).
• People currently experiencing a serious active infection requiring antibiotic or antifungal treatment, or who completed such treatment within the last 7 days.
• People whose cancer has never responded to any prior treatment (meaning it never shrank or disappeared with previous therapy).
• People with known or suspected cancer spread to the brain.
• People with serious heart conditions, including severe heart failure, unstable chest pain, a heart attack within the last 6 months, or serious uncontrolled heart rhythm problems.
• People with severe lung disease, including significantly reduced lung function or low blood oxygen levels at rest.
• People with other serious uncontrolled medical conditions that could be made worse by the study treatment.
• People with a history of another cancer within the past 5 years, unless it was a type that may be considered acceptable after discussion with the medical team (such as certain skin cancers, some early-stage cancers, or certain low-grade blood cancers — confirm with trial site).
• People with uncontrolled high blood pressure (blood pressure consistently at or above 160/100 mmHg).
• People with a history of scarring or inflammation of the lungs (interstitial lung disease, pneumonitis) or high blood pressure in the lungs.
• People with active hepatitis B or hepatitis C infection with a detectable viral level despite antiviral treatment.
• People who need to take certain medications that strongly interact with the study drug (including some antifungals and antibiotics such as ketoconazole, itraconazole, erythromycin, clarithromycin, rifampin, and others) — these medications would need to be stopped before starting the study drug (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.